Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06804811 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 79 to 78 Eligibility criteria expanded, about 23 words · Secondary endpoints: details revised at 2 of 14 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 2 of 14 entries
  2. Trial sites reduced: 86 → 79 locationsv10
  3. Site details revised at 1 of 86 sitesv9
  4. Study sites revised (86)v8 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 87 to 86v7
Show 5 earlier versionsHide 5 earlier versions
  1. Site details revised at 2 of 87 sitesv6
  2. Study sites: 2 to 87 Start date changed from estimate of Oct 15, 2025 to Nov 13, 2025v5 Show 1 more changeShow less
    • Start date changed from estimate of Oct 15, 2025 to Nov 13, 2025
  3. Trial status: Not Yet Recruiting to Recruiting Start date: Aug 8, 2025 to Oct 15, 2025 · Study sites: 0 to 2v4 Show 2 more changesShow less
    • Start date: Aug 8, 2025 to Oct 15, 2025
    • Study sites: 0 to 2
  4. Re-verified, no change to tracked fieldsv3
  5. Study Status, Referencesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.
Trial Details
NCT Number NCT06804811
Lead Sponsor Incyte Corporation
Conditions NonSegmental Vitiligo
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov